Lexicon Pharmaceuticals(US:LXRX) Newsfilter·2024-08-07 12:00Core Insights - Lexicon Pharmaceuticals, Inc. will present three posters at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists from August 9 to 12, 2024 [1][2] Group 1: Poster Presentations - The three presentations will occur on August 10, 2024, from 12:15 to 1:15 p.m. CT [2] - The topics include: - Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease [2] - Impact of Sotagliflozin as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes [2] - Patient-Reported Burden of Disease in Diabetic Peripheral Neuropathic Pain [2] Group 2: Clinical Significance - Individuals with type 1 diabetes and chronic kidney disease are at high risk for kidney failure and cardiovascular events due to poor glycemic control [3] - The company aims to engage diabetes educators at the conference regarding the clinical effects of sotagliflozin as an adjunct to insulin for these patients [3] Group 3: Product Information - Sotagliflozin is an oral inhibitor of SGLT2 and SGLT1, which are proteins involved in glucose regulation [4] - The drug has been studied in approximately 20,000 patients across various conditions, including heart failure and diabetes [4] Group 4: Additional Drug Development - LX9211 is another investigational drug by Lexicon, targeting neuropathic pain through inhibition of AAK1 [5] - LX9211 has received Fast Track designation from the U.S. FDA for diabetic peripheral neuropathic pain [5] Group 5: Company Overview - Lexicon Pharmaceuticals focuses on pioneering medicines that transform patients' lives through its Genome5000™ program, studying nearly 5,000 genes [6] - The company has launched INPEFA® (sotagliflozin) in the U.S. and has a pipeline of drug candidates in various stages of development [6]